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Successful thermal ablation using radiofrequency has been reported in various tumors including liver or kidney tumors.
Nonsurgical minimally invasive ablative therapy such as radiofrequency ablation (RFA) has been reported to be a safe and efficient
treatment option in managing symptomatic cold thyroid nodules or hyperfunctioning thyroid nodules. Pressure and cosmetic
symptoms have been shown to be significantly improved both in the short and long terms after RFA. For hyperfunctioning thyroid
nodules, RFA is indicated for whom surgery or radioiodine are not indicated or ineffective or for those who refuse surgery or radio-
iodine. Improvement of thyroid function with decreased need for antithyroid medications has been reported. Complication rate
is relatively low. By reviewing the current literature, we reported its efficacy and complications and compared the efficacy of RFA
relative to other ablative options such as ethanol ablation and laser ablation.
1. Introduction
Thyroid nodules are commonly found and they pose one of
the most common clinical problems for primary physicians
and specialists. Clinically palpable nodules are found in 5–
10% of the normal population and nonclinically palpable
nodules such as those found incidentally on ultrasound (US)
occur in up to 67% [1–3]. With the increasing use of US, it is
expected that more and more asymptomatic thyroid nodules
would be detected [4].
Although the majority of these nodules are benign and
may not cause symptoms, some are occasionally associated
with pressure or thyrotoxic symptoms [5, 6]. Surgery is the
treatment of choice for these nodules but may be associ-
ated with certain operative morbidity, unsightful scar and
permanent hypothyroidism [7–10]. The alternatives include
ethanol ablation (EA) [11–13], radiofrequency ablation (RFA)
[5, 11, 14–24], percutaneous laser ablation (PLA) [6, 25], high-
intensity focused ultrasound (HIFU) [26], and microwave
ablation [27, 28]. Nonsurgical, minimally invasivemodalities,
like ethanol ablation and laser ablation, have been reported
to be an effective option in treating thyroid nodules [12, 13,
25, 29–33]. RFA is a safe percutaneous ablative technique in
treating liver tumors [34, 35]. Since the first reported series
in 2006 [36], there had been numerous studies showing its
efficacy and safety in treating benign cold and hyperfunction-
ing thyroid nodules [5, 11, 14–24]. In this paper, we described
the basic principles, patient selection, procedure, efficacy, and
complications of RFA and its efficacy relative to other ablation
modalities.
2. Basic Principles of RFA
RFA refers to hyperthermic ablation by high frequency
alternating electric current oscillating between 200 and
1200 kHz [37]. By applying an electrode into nodule, a high-
frequency alternating current is generated and passed into
the surrounding tissue. It thus induces rapid vibration of
surrounding ions and frictional heat. Coagulative necrosis
and irreversible damage is induced near the electrode at
temperature between 50∘C and 100∘C [38]. Temperature
higher than 100∘Cwould lead to vaporization and carboniza-
tion which result in increased impedance of the tissue and
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thus interrupted the transferal of electric current and heat
energy [38]. Beside the frictional heat produced by oscillating
ions, conduction of heat causes further damages to the
surrounding remote area in a slower manner [37, 39]. This
forms the basic principles of RFA.
The principles of heat conduction have been demon-
strated in one recent experimental study using the pig animal
model [40]. In this experimental study, temperature mea-
surements around the RFA electrode in the porcine thyroid
gland were taken.Themaximum temperature at a distance of
5mm from the RFA electrode was between 44∘C and 61∘C
while, at a distance of 10mm, a maximum temperature of
53∘Cwas achieved. Even at this temperature, there were signs
of irreversible cell death damage in the region of the thermal
lesions [40].
3. Patient Selection
In 2012, theKorean Society ofThyroid Radiologymade a con-
sensus statement regarding the treatment of thyroid nodules
with RFA [41]. Essentially, RFA is indicated either for patients
with nodule-related symptoms or with hyperfunctioning
nodule(s) which is causing thyrotoxicosis. It is important
that, before the ablation, the nodule should be confirmed to
be benign in nature with at least two separate US-guided
fine-needle aspiration cytologies and/or core biopsies [42,
43]. Report of RFA incompletely treating primary thyroid
carcinoma was present and histological report reviewed the
inadequacy of RFA in treating primary thyroid carcinoma
[44], and there was no evidence in supporting the treatment
benefit of RFA in primary thyroid carcinoma. On the other
hand, a cytological diagnosis of follicular or indeterminate
lesion requires histology to exclude malignancy. Therefore,
the consensus statement did not recommend RFA for fol-
licular lesion or a nodule suspicious of malignancy [41]. In
general, RFA is a safe procedure. However, we should be
cautious in application of RFA in patients who are either
pregnant or having history of serious heart problems [5, 41,
45–47]. Since there had been reports of cardiac complication
during RFA for liver tumors [45, 48], patients with serious
heart disease should have continuous cardiac monitoring
during and after RFA of thyroid nodules.
4. Procedural Steps
During the procedure, the patient should be positioned in
supine with neck slightly extended. Local anesthetic with
lignocaine or xilocaine is then injected underneath the skin
near the cervical-surrounding soft tissue and thyroid capsule
[23, 49, 50]. Some would also administer premedication
of fentanyl and midazolam to minimize discomfort [51].
Ground adhesive pads are adhered to both thighs and are
connected to RF generator, and the generator was connected
to RF electrode.
There are two types of RF device and technique for
thyroid nodules. The first technique is called the “fixed
ablation” technique. This technique was popularized by an
Italian group. It involves the use of a multi-tined expandable
electrode [22–24]. The electrode is a 14-gauge, 10 cm long,
four-hook expandable needle [14, 22]. Under US guidance,
the electrode is inserted along the greatest dimension of the
nodule.The hook is then opened to amaximumof 3.5 cm and
placed with caution so as to avoid injury to vital structures.
Each hook is recommended to be 10mm away from thyroid
capsule, 5∼6mm from pseudocapsule of the outer edge of
nodule, and 15mm from heat-sensitive cervical structures
[22]. Lidocaine is injected into superficial cervical tissue and
on the thyroid gland capsule under US guidance. Correct
position of electrode tips and hook is assessed by US. With
this technique, a spherical ablative zone is usually achieved.
After the ablation, the hooks are retracted and the electrode
is slowlywithdrawn after the RF energy has been switched off.
The second technique is called the “moving shot” tech-
nique. This technique was first described by Baek et al. in
Seoul, Korea. In contrast to the fixed ablation technique,
a straight internally-cooled electrode is used [15, 16]. The
electrode is usually 15 cm in length and 17 gauge in size
with 1 cm active tip [15, 36, 52]. Recent modifications have
allowed even shorter (7 cm shaft length) and smaller (18-
19 gauge) electrode with active tips around 0.5, 0.7, 1, 1.5,
and 2 cm [6, 16]. With these shorter and smaller electrode,
it allows better control and variation of ablation option
in treating small or vital structure closed thyroid nodule.
In the “moving shot technique” [15, 16], the target thyroid
nodule is divided into multiple small conceptual ablation
units and during the procedure, each conceptual unit is being
ablated by the moving ablation electrode tip. The electrode
is inserted through the isthmus under the US guidance.
As a result, the whole course of electrode could be seen
and that greatly reduces the risk of injury of the nearby
structures. The ablation first starts from the deepest layer up
and so the electrode is slowly withdrawn to the surface. It
is important that the region close to the trachea-esophageal
groove be underablated in order to avoid injury to the
recurrent laryngeal nerve, trachea, and esophagus as this area
is often referred to as the “danger triangle”.
5. Short- and Long-Term Clinical
Efficacy of RFA
RFA therapy has mainly been aimed at decreasing pressure
symptoms, improving the cosmetic results as well as resolving
thyrotoxic status in hot nodules. Table 1 shows the results
of volume reduction of cold thyroid nodule after RFA [53].
For cold nodules, the efficacy of RFA has mainly been
evaluated in terms of reduction of nodule volume, pressure
symptoms, and cosmetic symptoms. The reported mean
volume reductions at 1- and 6-month were 33∼53% and
51∼92%, respectively [15, 22]. Most patients have reported
improvement in pressure symptoms and cosmetic symptoms
[5, 15, 17, 23, 24, 52]. Faggiano et al. reported a prospective
study and found that RFA was far superior to conservative
treatment [24]. In this study, 20 patients were assigned to the
RFA group while the other 20 patients to the control group.
After 12 months, patients in the RFA group had significantly
decreased mean nodule size (13.3 to 1.8mL, 𝑃 < 0.001)
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Sung et al. [11] 21/21 <10% 1–6 Internally cooled 1–3 (1.67) 10.2 92
Deandrea et al. [22] 10/9 >30% 6 Multitinedexpandable 1 38.7 31.7 46.3
Spiezia et al. [23] 66/66 >30% 12–24 Multitinedexpandable 1–3 (1.4) 21.1 43.7 76.6
Lee et al. [52] 27/27 10–50% 6–38 Internally cooled 1–4 (1.6) 14 97
Jang et al. [19] 20/20 <50% 6–43 Internally cooled 1-2 (1.1) 11.3 92
Baek et al. [17] 15/15 >50% 6–8 Internally cooled 1 7.5 49 80
Ha et al. [5] 14/11 >50% 7–92 Internally cooled 9.7 87.2









Faggiano et al. [24] 10/10 >70% 12 Multitinedexpandable 1 13.3 36.5 84.9
Kim et al. [36] 35/30 0–100% 1–18 Internally cooled 1 6.3 47 64
Jeong et al. [15] 302/236 0–100% 1–41 Internally cooled 1–6 (1.4) 6.1 58 84
Lim et al. [20] 126/111 0–100% 36–81 Internally cooed 1–7 (2.2) 9.8 93.4
while, in the control group, the mean nodule size was nearly
static (11.2 to 11.8mL, 𝑃 > 0.05). The symptom score was
also significantly improved in the RFA group (3.4 to 0.6
out of 6, 𝑃 < 0.001) and there was a trend of worsening
symptoms in the control group (3.0 to 4.1 out of 6, 𝑃 > 0.05).
Furthermore, the effect of RFA appeared to be durable. After
a 2-year follow-up, a mean of 79.4 ± 2.5% decrease in nodule
size (baseline size 24.5 ± 2.1mL) was observed in an Italian
study [23]. Compressive symptoms improved in all patients
and were completely resolved in 88% patients [23]. Similarly,
Lim et al. reported a high mean nodule volume reduction
(93.5±11.7%) after amean follow up of 49months. Regrowth
of more than 50% was very uncommon (5.6%) [20].
However, it would appear that its efficacy solely depends
on the proportion of cystic component within the ablated
nodule. For cystic nodules with <10% solid component, RFA
could achieve >90% reduction at 6-month after ablation
[11, 21, 36]. However, relative to EA, RFA was not superior
and required more sessions and was more expensive [11, 21].
In a recent randomized study of single-session treatment of
benign cystic thyroid nodules, the mean volume reduction
was 96.9% in EA while it was 93.3% in RF ablation (𝑛 =
21 for each) (difference, 3.6%; lower bound of the one-
sided 95% CI of the difference, 1.2%), thus demonstrating
the noninferiority of EA to RFA [21]. The authors concluded
that EA may be the first-line treatment modality for cystic
thyroid nodules, which has comparable therapeutic efficacy
to, but is less expensive than, RF ablation [21]. Therefore, EA
would still be the first-line ablative measure for cystic nodule.
On the other hand, predominant cystic nodule (10–50% solid
component)might be suitable for RFA as 6.1–21% failure rates
in EA were reported for this type of nodules [19, 54, 55].
RFA is generally good in treating the solid component of
these refractory nodules [19, 52]. In predominantly solid or
solid nodule (i.e.,>50% solid component), RFA could achieve
a 23 to 37% volume reduction at the 1st month and 51 to
77% reduction at the 6th month [16, 24, 36]. The rate of
volume reduction appears to be maximum after 1–3 months
and tends towean off after 6months [15, 36]. Besides presence
of high cystic content [15–17, 19, 20, 36], low vascularity of
nodule [16, 36] and nontoxic status [14] are good predictors
for volume reduction.
Table 2 shows the result in patients underwent RFA for
hyperfunctioning thyroid nodule. For benign hyperfunc-
tioning thyroid nodules, RFA not only reduces the volume
but also improves the functional status. The majority has
improved thyroid function and reduced the need for antithy-
roid medication [22, 24]. In fact, antithyroid medication
could be stopped in about 23 to 89% of the patients [16,
22]. In a largest reported series of 28 patients, Spiezia et al.
reported that all patients with pretoxic thyroid nodule and
53% of patients with toxic thyroid nodule stopped antithyroid
medication at 12-month follow up after RFA. Relative to
cold nodules, ablation of hyperfunctioning thyroid nodules
achieves lower volume reduction (60% versus 76% at 12
month) [23] and requires more number of sessions (2.2
versus 1.4) [15, 16]. In addition, it is important to be more
cautious during ablation because incomplete ablation leading
to nodule regrowth and hyperthyroid relapse appeared more
common in ablation of hot nodules.Therefore, more sessions
of RFA are generally needed [16].
6. Complications
Various complications have been described during RFA and
they include pain, voice changes, skin burn, hematoma,
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Deandrea et al. [22] 23/22 6 22.5 22.7% 77.3% 5.1 2.6∗
Spiezia et al. [23] 28/28 12–24 32.7 Pretoxic: 100%Toxic: 53% 7.9 4.2
∗
Baek et al. [16] 9/9 6–17 15 88.9%
Faggiano et al. [24] 10/10 12 13.3 40% 40% 6.5 2.3∗
∗
𝑃 < 0.05.
nodule rupture, and thyroid function disturbance. Most of
the patients recover well with proper treatment with very
few complications [5, 16–18, 23, 24, 33, 56]. In a Korean
multicenter study involving 1459 patients, there were 3.3%
patients with complications and, of these, 1.4% had major
complications.
Pain is the most common reported complication during
the procedure. It occasionally radiates to ear, shoulder, jaw,
and chest [6, 16]. However, it is usually self-limiting and
resolved soon when the power of RFA has been switched off.
It is controlled with simple oral analgesic and only 5.5% of
patients require analgesic for more than 2 days [15, 22, 57].
Voice change after RFA is uncommon (about 1%) but,
nevertheless, it is the most fearful and serious complication
[18]. It is likely caused by thermal injury to recurrent laryngeal
nerve or sometime vagal nerve in case of large thyroid
nodule. Most of the patients recover within 3 months [30].
To reduce this, underablation near tracheoesophageal groove
is recommended.
Unlike RFA in liver tumor, there have been no reports of
skin burn of thigh pads.This is probably because of the lower
energy used during ablation [37]. Skin burn at puncture site
has been reported and is usually of first degree. Most patients
recover from pain and skin color change within 7 days [18,
36]. Application of ice bag to puncture sitemight prevent skin
burn [18].
Haematoma after thyroidectomy is a distress compli-
cation [58]. It happens after RFA but could be managed
conservatively with the compression of neck for several
minutes [59]. It is usually caused by injury of perithyroidal
or anterior jugular vessels during electrode insertion. Proper
assessment of perithyroidal and anterior neck and use of
small size needle might prevent mechanical injury during
insertion [59].
Nodule rupture and thyroid function disturbances are
two potential late complications of RFA. Nodule rupture may
occur 1 month after RFA. It usually presents as a sudden
neck bulging and pain at the time of rupture. It is caused by
breakdown of thyroid capsule and internal bleeding. These
patients should be managed with antibiotics and closely
monitored since abscess formation is a potential sequel
requiring subsequent operation [18].
Transient thyrotoxicosis immediately after RFA has been
reported. All patients were asymptomatic and spontaneously
recovered within 1 month [15, 36]. Though subclinical
hypothyroidism in one patient was detected 6 month after
RFA, it was inconclusive in causal relationship of RFA and
hypothyroidism. Since this patient have elevated antithyroid
perioxidase antibody prior RFA, hypothyroidism might be
the progression of Hashimoto’s thyroiditis [16, 18]. Ha et al.
reported that RFA did not affect thyroid function even in
patients who had undergone lobectomy [5].
Although there were no fatal complication or ultramajor
complication, tracheal injury, esophageal injury, or perma-
nent voice changes have been reported, it is important to be
cautious during the procedure and always trace the electrode
tip before starting ablation [60]. There has been a complica-
tion of brachial plexus injury reported in 1459-patient study
[18]. Though rare, to minimize these complications, studying
preventive measures and following the consensus guidelines
are essential [41].
7. Comparison with Other Ablative Treatment
Other than RFA, otherminimally invasive ablativemodalities
have been described, including EA and PLA. EA has been
shown to be more effective in treating predominantly cystic
nodule (>90% cystic component) [12, 13, 29, 30] and less
for predominantly solid nodule [61]. Sung et al. tried to
evaluate the opium first-line treatment of thyroid cystic
nodule by comparing ethanol ablation and RFA [11, 21].
After a single treatment session, EA achieved similar and
noninferior outcome in terms of nodule volume, symptoms,
and cosmesis, compared to RFA [21]. However, fewer sessions
of ablation were needed in the EA group, and cost of each
session of ablation was also less expensive. Therefore, the
author concluded that ethanol ablation should be the first-
line treatment for cystic nodule. But there was still a role of
RFA in ethanol refractory thyroid nodules. About 20% of cys-
tic nodule was refractory to ethanol ablation [12, 19, 54, 55];
additional RFA could effectively treat incompletely resolved
thyroid nodule [52]. For predominantly cystic nodules (i.e.,
>20% solid component), EA is prone to incomplete ablation
and adding RFA might be needed for improved results [19].
Since the introduction of PLA in 2000, different stud-
ies have assessed its efficacy and safety in the ablation
of thyroid nodules [25, 31–33]. It has been recommended
by the guidelines of the American Association of Clinical
Endocrinologists, the Associazione Medici Endocrinologi
(Italian Association of Clinical Endocrinologists), the Euro-
pean Thyroid Association (AACE-AME-ETA) as a possible
option for treatment of benign thyroid nodules [57]. PLA
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could achieve a significantly larger ablation area [40], but
current studies have not shown a superiority over RFA
[6]. After PLA, comparable volume reduction rate to RFA
has been reported [6]. However, durability might not be
slightly inferior. Valcavi et al. reported a series of 122 patients
undergoing laser ablation of cold thyroid nodule [62]. At 3-
year follow-up, mean volume decreased 48 ± 33.1%, while
symptoms improved in 73% of patients. For the study of RFA,
Spiezia et al. reported a study of a 2-year follow-up in 94
patients, mean 79.4 ± 2.5% decrease in size of thyroid nodule
was noted and all patients have compressive symptoms
improved [23]. Similarly, Lim et al. reported a mean volume
reduction of 93.4±11.7% in a series of 111 patients undergoing
RFA with a 4-year follow-up [56]. However, the reported
series of laser ablation usually included patients with larger
thyroid nodule and the series of RFA included patients with
a higher cyst component. Thus, these results were difficult
to compare. Further study to differentiate the superiority of
either modality would be needed.
8. Conclusion
Nowadays, available reports of application of RFA in benign
thyroid nodules were mainly from two centers. The main
weaknesses of using RFA on the thyroid gland are sev-
eral folds and they include the lack of definitive histology,
possibility of incomplete nodule ablation, and surveillance
problems for the residual thyroid mass after RFA. However,
RFA appears to be an effective nonsurgical option to improve
pressure and toxic symptoms in biopsy-proven benign thy-
roid nodules. Preliminary reports showed satisfactory results
in volume reduction, pressure symptoms, and cosmetic
symptoms, and these results appear to be sustained in the
long term.Therefore, proper selection of patient with benign
nodule for RFA and subsequent monitoring were needed.
Further studies were needed to support its routine use in
thyroid nodule.
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